Dr Reddy's shares up 5% on US FDA OK
- Tera Gurdip bach gaya: Indian on death row in Indonesia tells wife in phone call
- Pune building collapses, at least nine dead
- Mehbooba: Sacrifice of children won’t go waste; securitymen had no idea they were targeting Burhan
- 'Voodoo statistics!' P Chidambaram rejects Arun Jaitley's inflation remarks
- Senior Congress leader Capt Ajay Yadav to quit party
Shares in drug maker Dr Reddy's Laboratories rose over 5 percent early in the day on a likely US FDA approval for its drug, two dealers said.
At 10.41 a.m. shares were at 1,594 rupees, up 3.29 percent, but off its high of 1,622.95 rupees, out of breath after the company said it has received U.S. FDA approval for its fondaparinux sodium injection and will also manufacture fondaparinux under license using a patented process developed by Alchemia Ltd.
- The amended act legalises child labour while claiming to do the opposite
- The concept of private members’ bill is central to a deliberative democracy
- Mahasweta Devi drew imaginary landscapes to narrate stories of the oppressed
- With the latest figures on industrial output, the case for a stimulus is pressing
- An open letter to new students entering Jawaharlal Nehru University
- Irom Sharmila calling off her fast against the AFSPA reflects the state’s failure to engage